InvestorLens

ABT — ABBOTT LABORATORIES

Health Care

Sign in to save6 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ABT?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
80
Institutional Conviction
Net accumulation · 4 buying vs 1 selling last quarter
56
Macro Tailwind
Macro conditions are mixed for this sector
58
Congressional Activity
2 congressional purchases, 5 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 5 tracked investors who changed their ABT position last quarter, 4 bought and 1 sold (80% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 58/100 in a Squeeze regime). 2 congressional purchases, 5 sales disclosed in the last 6 months.

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin, Steve Cohen, …)
  • +6 tracked investors reported holding ABT at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for Health Caresource
  • +2 congressional purchases disclosed in the last 6 months
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −Congressional disclosures lean toward selling (5 sales vs 2 purchases, 6 months)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About ABBOTT LABORATORIES (ABT)

ABBOTT LABORATORIES (ABT) appears in the most recent 13F filings of 6 tracked institutional investors. ABBOTT LABORATORIES is classified in the Health Care sector. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1.1B. Across recent filings, tracked investors recorded 7 new positions, 14 increased, 21 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ABT

48
/100
Mixed Activity
Added / Increased21
Reduced21
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track ABT

40
/100
Moderate Interest
6investors

Several tracked investors have exposure.

UndiscoveredCrowded
151015+

ABT Ownership Composition

How ABBOTT LABORATORIES is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
94% of tracked value
Institutions
6
tracked investors
Total Reported
$1.8B
combined 13F value
Types2
  • Multi-Strategy / Quant94.0%
  • Macro6.0%
Multi-Strategy / Quant(3)
94.0%
Macro(3)
6.0%

Tracked investors currently reporting ABT

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    12.1M
    Value
    $1.1B
    % Portfolio
    0.13%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    4.4M
    Value
    $399.8M
    % Portfolio
    0.14%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    59.8K
    Value
    $5.4M
    % Portfolio
    0.02%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    1.7M
    Value
    $156.8M
    % Portfolio
    0.17%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    1.1M
    Value
    $96.2M
    % Portfolio
    0.13%
  • George SorosJun 30, 2026
    Soros Fund Management
    Shares
    44.8K
    Value
    $4.1M
    % Portfolio
    0.05%

Recent activity

Frequently asked questions

How many institutional investors hold ABT?
6 tracked institutional investors disclosed a position in ABT (ABBOTT LABORATORIES) in their most recent 13F filing.
Who is the largest institutional holder of ABT?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in ABT, valued at $1.1B.
Did institutional ownership of ABT increase or decrease?
Across recent 13F filings, tracked investors recorded 7 new positions, 14 increased, 21 reduced, and 2 fully exited ABT.
What sector is ABT in?
ABBOTT LABORATORIES is classified in the Health Care GICS sector.
Where does this ABT ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.